Background. Sildenafil has been found to improve exercise capacity and haemodynamic parameters in patients with various pulmonary disorders. This study was undertaken to evaluate its efficacy in severe chronic obstructive pulmonary disease (COPD).
Methods. In this double-blind, randomised, placebo-controlled study, 37 patients with severe COPD received either sildenafil or placebo for 12 weeks. Distance covered in six-minute walk test (6MWD) was taken as primary end-point. Pulmonary artery pressure (PAP) was measured as secondary end point.
Results. Thirty-three patients (15 in sildenafil arm and 18 in placebo arm) completed the study. Non-parametric tests were used for comparison. There was significant increase in 6MWD from baseline after three months of follow-up in sildenafil users (median change in distance covered in six-minute walk test (Ä6MWD)=190m) as compared to placebo users (Ä6MWD=0m, p< 0.05). The PAP decreased significantly (÷2=14.94, p<0.05) in sildenafil group after three months, while it did not change significantly among placebo group (÷ 2=3.84, p>0.05).
Conclusion. Sildenafil improved 6MWD and PAP in patients with severe COPD.
This trial has been registered with Indian Council of Medical Research (ICMR) Trial Registry. [CTRI Registry Number: CTRI/2009/091/000017]
Brown CD, Benditt JO, Sciurba FC, Lee SH, Crineq GJ, Morenifar Z, et al. Exercise testing in severe emphysema: association with quality of life and lung function. COPD 2008;5:117-24.
Budweiser S, Heidtkamp F, Jorres RA, Heinemann F, Arzt M, Schroll S, et al. Predictive significance of six minute walk distance for long term survival in chronic hypercapnic respiratory failure. Respiration 2008;75:418-26.
Macintyre NR. Mechanism of functional loss in patients with chronic lung disease. Respir Care 2008;53:1177-84.
Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36:752-8.
Naeija R, Barbera JD. Pulmonary hypertension associated with chronic obstructive lung disease. Crit Care 2001;5: 586-9.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Robin LJ, Badesch D, et al. Sildenafil citrate for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
Sheth A, Park JE, Ong YE, Ho TB, Madden BP. Early hemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascular Pharmacol 2005;42:41-5.
Alp S, Skrygan M, Schmidt WE, Bastian A. Sildenafil improves hemodynamic parameters in COPD: an investigation of six patients. Pulm Pharmacol Ther 2006;19:386-90.
Rietema H, Holverda S, Bogaard HJ, Marcus JJ, Smit HT, Westerhof N, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008;31:759-64.
ATS Committee on proficiency standards for clinical pulmonary function laboratories. ATS statement: Guideline for six minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
Mcgoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest 2004;126:14s-34s.
McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-802.
Madden BP, Allenby M, Loke TK, Seth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascular Pharmacol 2006;44:372-6.
Madden BP, Sheth A, Wilde M, Ong YE. Does sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease? Vascul Pharmacol 2007;47:184-8.
Lewis GD, Shah R, Shazad K, Camuso JM, Pappagianopoolos PP, Hung J, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-62.
Keogh AM, Jabbour A, Hayward CS, Macdonald PS. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. Vasc Health Risk Manag 2008;4:1111-3.
Michelaus ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
Stanopoulos I, Manolakoqlou N, Pitsiou G. Sildenafil may facilitate weaning in mechanically ventilated COPD patients: a report of three cases. Anaesth Intensive Care 2007;35:610-3.
Wong RC, Koh GM, Choong PH, Yip WL. Oral sildenafil therapy improves health related quality of life and functional status in pulmonary arterial hypertension. Int J Cardiol 2007;119:400-2.
Holverda S, Rietema H, Bogaard HJ, Westerhof N, Postmus PE, Boonstra A, et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 2008;21:558-64.
Nagendran J, Archer SL, Soliman D Gurtu V, Moudgil R, Haromy A, et al. Phosphodiesterase type 5 is highly expressed in hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improve contractility. Circulation 2007;116:238-48.
Van Wolferen SA, Boonstra A, Marcus JT, Marques KM, Bronzwaer JG, Postmus PE, et al. Right ventricular reverse remodelling after sildenafil in pulmonary hypertension. Heart 2006;92:1860-1.
Charan NB. Does sildenafil also improve breathing? Chest 2001;120:305-6.
Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclise. Eur J Pharmacol 2007;572:12-22.
